Issue of B Shares
3 December 2018
Issue of B Shares as Part of the B Share Scheme
Further to the shareholder circular issued by McBride plc (the Company) on 6 September 2018 and the passing of an ordinary resolution at the annual general meeting of the Company held on 23 October 2018, the Company announces that on 30 November 2018, 5,111,957,284 non-cumulative redeemable preferences shares of 0.1 pence each (B Shares) were issued by the Company. On the same day 5,696,243,081 B Shares were redeemed and cancelled in accordance with the elections made by the Company's ordinary shareholders. 976,087,726 B Shares are being retained by the Company's ordinary shareholders who did not elect to redeem their B Shares.
The B Shares do not carry voting rights, except at any general meeting at which a resolution to wind up the Company is to be considered in which case the holders of B Shares shall have the right to attend the general meeting and shall be entitled to speak and vote only on such resolution. No application will be made to the UK Listing Authority or to the London Stock Exchange for any of the B Shares to be admitted to the Official List or to trading on the London Stock Exchange main market for listed securities, nor will the B Shares be admitted to trading on any other recognised investment exchange.
Following this issue the Company has a total of 182,798,259 ordinary shares (excluding ordinary shares held in treasury) in issue and holds 42,042 ordinary shares of 10p each in treasury. The Company does not hold any B Shares in treasury. The total number of voting rights in the Company is 182,798,259 and this figure can be used by shareholders as a denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA Disclosure and Transparency Rules.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.